Cadrenal Therapeutics (CVKD) and Its Competitors Critical Analysis

Cadrenal Therapeutics (NASDAQ:CVKD) is one of 955 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Cadrenal Therapeutics to similar companies based on the strength of its dividends, institutional ownership, analyst recommendations, profitability, earnings, valuation and risk.

Valuation and Earnings

This table compares Cadrenal Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	-$8.36 million	-0.62
Cadrenal Therapeutics Competitors	$1.66 billion	$154.05 million	-3.88

Cadrenal Therapeutics’ competitors have higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Cadrenal Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics’ competitors have a beta of 0.80, suggesting that their average share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cadrenal Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	0	0	2	0	3.00
Cadrenal Therapeutics Competitors	6095	17833	42985	885	2.57

Cadrenal Therapeutics currently has a consensus price target of $3.50, indicating a potential upside of 714.33%. As a group, “Pharmaceutical preparations” companies have a potential upside of 85.78%. Given Cadrenal Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than its competitors.

Profitability

This table compares Cadrenal Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-128.67%	-117.76%
Cadrenal Therapeutics Competitors	-2,643.56%	-227.01%	-28.96%

Insider and Institutional Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 58.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cadrenal Therapeutics beats its competitors on 8 of the 13 factors compared.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.